Validate the right targets. Skip the dead ends.
Every validation experiment costs months and real money. Nuclens checks the existing evidence for a target first (localization, tumor expression, internalization, essentiality, clinical history), so your lab only spends time on targets that deserve it.
Free to search and rank. Pay only when you generate a full decision report.
What is drug target validation?
Drug target validation is the experimental demonstration that modulating a target changes a disease as intended, with acceptable safety. The core methods are genetic perturbation (CRISPR, RNAi), pharmacological tool compounds, expression studies in patient tissue and in vivo models. Nuclens does not replace these experiments. It checks the existing evidence first, so labs validate only the most promising targets.
The most expensive experiment is the one the literature already answered.
Target validation is where time and budget really go. A lot of it is spent confirming things public data could have told you, or discovering deal-breakers too late.
| Task | The manual way | With Nuclens |
|---|---|---|
| Is it really on the cell surface? | Order antibodies, run flow cytometry, wait | UniProt localization shown up front, with evidence source |
| Is it in patient tumors? | Source tissue, stain a microarray | Human Protein Atlas IHC across 20 cancers, % of patients positive |
| Does it internalize? | Set up an internalization assay from scratch | Literature evidence for and against, with PMIDs, in seconds |
| Is it essential? | Run your own CRISPR knockout | DepMap CRISPR effect across 1,000+ cell lines |
| Has anyone tried? | Hunt through trial registries and conference abstracts | Clinical stage and active trials per target |
| Result | Months before you know it was a dead end | Dead ends flagged before the first experiment |
What Nuclens screens, every time you ask.
Example: in lung cancer, 4,217 cell-surface proteins show detectable tumor staining in Human Protein Atlas immunohistochemistry. See the ranked lung cancer targets →
A target validation evidence check in three steps.
Enter the target (or ten)
Look up the targets you are about to validate, or let Nuclens rank candidates for your indication.
See the prior evidence, for and against
Localization, tumor expression, internalization, shedding, essentiality and clinical history, each with its source, plus flags where the evidence conflicts.
Design experiments that answer new questions
Generate a report with the open questions called out, so your validation plan tests what is actually unknown.
How to validate a drug target: the methods and experiments that matter.
Target validation is proving that modulating a target changes disease in the way you expect, and that it is safe to do so. It is the step where most targets fail. When Bayer tried to reproduce published target data in-house, the results matched in only about a quarter of projects (Prinz et al., 2011).
Genetic validation
CRISPR knockout, CRISPRi/a and RNAi test whether losing (or gaining) the target changes the disease phenotype. They are also the best check that a drug works through its intended target (Lin et al., 2019).
Pharmacological validation
Tool compounds, chemical probes and antibodies show that modulating the target with a molecule reproduces the genetic effect.
Human genetic evidence
Natural variants in people act as lifelong experiments, the strongest predictor of clinical success.
Patient tissue validation
IHC on tumor microarrays confirms the target is expressed in patients, not just cell lines, and shows how many patients are positive.
In vivo models
Xenografts, PDX and genetically engineered mice test efficacy and on-target toxicity in a whole organism.
Modality-specific assays
For radioligands: binding affinity and receptor density, internalization and retention, biodistribution and dosimetry, then imaging with a diagnostic pair.
Computational vs. experimental target validation. Public data can't prove a target works; only experiments can. But it can tell you, cheaply and fast, whether a target has already failed a basic test: it's intracellular when you need surface access, it's absent from patient tumors, it sheds into the blood. Checking that evidence first is the cheapest target validation step there is. That's the step Nuclens automates.
Target validation experiments for radioligand therapy. RLT adds its own checklist: saturation binding to measure receptor density, internalization assays to confirm the radionuclide is retained, biodistribution studies to measure uptake in kidney, liver and salivary glands, and dosimetry to confirm a therapeutic window. Read more on how normal-tissue expression predicts dosimetry risk.
What Nuclens does not do. Nuclens is a first-pass evidence layer. It doesn't replace wet-lab validation, clinical dosimetry or expert judgement, and AI-extracted literature findings are flagged for you to verify. What it does is make sure the targets you validate are the ones that survive a hard look at the existing evidence.
Give your team its weeks back.
Know what the literature already says about internalization, shedding and expression before you design the assay.
Stop discovering deal-breakers in month six. Screen out targets that fail on existing evidence first.
Allocate validation budget to targets with the strongest prior evidence, and document why.
Common questions
What is target validation in drug discovery?
Target validation is the experimental demonstration that modulating a target changes a disease in the desired way, with acceptable safety. It follows target identification and prioritization and is required before committing to a full drug discovery program.
What are the main target validation methods?
Genetic methods (CRISPR knockout, CRISPRi/a, RNAi), pharmacological methods (tool compounds, antibodies, chemical probes), human genetic evidence, expression studies in patient tissue, and in vivo disease models. Modality-specific assays are added on top, such as internalization and biodistribution for radioligands.
How do you validate a drug target?
First, check the existing evidence: localization, expression in patients, essentiality, genetic association and prior clinical attempts. Then design experiments for the open questions: genetic and pharmacological perturbation, patient-tissue confirmation and in vivo efficacy and safety. Nuclens covers the evidence check in minutes.
Can AI validate a drug target?
No, and you should be wary of anyone who says it can. AI can assemble and weigh existing evidence, flag contradictions and point out what is still unknown, which makes experimental validation faster and better targeted. The experiments themselves still have to be run.
What target validation experiments are needed for radioligand therapy?
Typically: saturation binding to measure receptor density, internalization and retention assays, in vivo biodistribution to measure normal-organ uptake, dosimetry, and imaging with a diagnostic radioligand. Nuclens surfaces literature evidence on internalization and shedding before you start.
Why do so many targets fail validation?
Often because the original evidence doesn’t reproduce, the target is not expressed in enough patients, or drug activity turns out to be off-target. Checking independent public evidence early catches many of these failures before they cost months of lab time.
Validate targets that deserve it.
Check the evidence for any oncology target free, before you commit a single experiment.